https://www.selleckchem.com/ALK.html
L-arginine (L-Arg) depletion induced by randomly PEGylated arginine deiminase (ADI-PEG2 can treat arginosuccinate synthase (ASS)-negative cancers, and ADI-PEG20 is undergoing phase III clinical trials. Unfortunately, ASS-positive cancers are resistant to ADI-PEG20. Moreover, the yield of ADI production is low because of the formation of inclusion bodies. Here, we report a thermostable arginine-depleting enzyme, Bacillus caldovelox arginase mutant (BCA-M Ser161-Cys161). An abundant amount of BCA-M was easily obtained via high cell-density ferme
Like
Comment
Share
